Arthrosamid presents a fresh approach to treating knee osteoarthritis, providing patients with a viable option to existing therapies. The treatment employs an inventive non-biodegradable hydrogel technology composed of 97.5% water and 2.5% cross-linked polyacrylamide backbone. Upon injection into the knee joint, Arthrosamid acts as a cushion, assuaging pain and delivering secure and long-lasting relief in a single shot.
Arthrosamid is a type of injection known as an intra-articular polyacrylamide hydrogel (iPAAG) used to alleviate the symptoms of knee osteoarthritis. It works by replenishing the synovial fluid’s thickness, enhancing joint lubrication, and cushioning. Additionally, it creates a cushioning effect by integrating into the synovium of the inner joint capsule.
Arthrosamid is administered through a single injection into the knee’s intra-articular cavity by a qualified specialist, such as an orthopaedic surgeon or rheumatologist. Prior to the injection, a local anaesthetic is given to numb the area around the knee, which may cause a slight stinging sensation. Unlike surgery, the injection is a minimally invasive procedure that can be done on an outpatient basis. Before the injection, antibiotics are provided to prevent any potential infection risk.
Arthrosamid is an intra-articular polyacrylamide hydrogel injection used for the symptomatic treatment of knee osteoarthritis. Upon injection into the inner joint cavity, it restores the thickness of the synovial fluid, enhancing joint lubrication and cushioning. Furthermore, Arthrosamid integrates into the synovium of the inner joint capsule, producing a cushioning effect.
The knee is cleaned prior to the Arthrosamid injection
The injection of Arthrosamid is performed with the help of ultrasound
Arthrosamid is injected using a needle.
The needle is removed, and a plaster is placed over the injection site.
Arthrosamid acts to cushion the joint, resulting in a reduction in pain, stiffness, and improved movement. The hydrogel is non-degradable, providing long-lasting relief, which can enhance your quality of life. According to clinical trials, patients experienced a considerable reduction in pain symptoms by the fourth week after their injection. Unlike other injectable treatments, this reduction was sustained at the two-year follow-up period.
Several clinical trials of Arthrosamid have not reported any severe hydrogel-related side effects. Mild to moderate injection site pain and swelling were the most frequently reported side effects, which were typically short-lived. The hydrogel’s safety profile has been established over the past two decades, as it has been used for various indications in the body.
Arthrosamid has only been studied for the treatment of knee osteoarthritis. Therefore it is currently only recommended for use in the knee.
A polyacrylamide hydrogel is a type of cross-linked polymer material that can retain a significant amount of water while retaining its structure, and its high water content gives it a level of flexibility similar to natural tissue. Arthrosamid, a hydrogel, is an inert and non-pyrogenic polymer gel composed of 97.5% sterile water and 2.5% cross-linked polyacrylamide, and it has the ability to exchange water.
In contrast to viscosupplement injections like Hyaluronic Acid (HA), Platelet Rich Plasma (PRP), and regenerative stem cell therapy, Arthrosamid has a unique characteristic of becoming an integral component of the soft synovial tissue in the joint capsule, resulting in prolonged and sustained pain relief.
The use of Arthrosamid intra-articular (IA) polyacrylamide gel (iPAAG) to alleviate pain symptoms associated with knee osteoarthritis is considered safe. In clinical trials, the most frequent adverse events observed were mild to moderate injection-related pain or mild swelling during the initial weeks to months following the injection.
Arthrosamid has the ability to cushion the joint, resulting in a reduction of pain, stiffness, and improved movement. It has been proven to be a safe treatment option that provides long-lasting relief and can improve the overall quality of life. In a significant trial, over 70% of patients reported experiencing these benefits.
Wear and tear are likely the main cause of the inflammatory response. However, Arthrosamid can be injected into the region surrounding the inner joint capsule to restore viscosity to the synovial fluid, improving lubrication and load distribution. Arthrosamid also integrates into the synovium of the inner joint capsule, resulting in a cushion-like effect.
Research has indicated that the pain-reducing effects of Arthrosamid can last for up to a year. However, initial investigations have suggested longer-lasting effects, potentially lasting several years. Two significant trials are currently monitoring patients for five years to determine the full extent of the sustained and long-acting benefits of Arthrosamid.
By providing a single 6ml injection, Arthrosamid can reduce pain and stiffness, and improve movement, leading to long-lasting and sustained pain relief and an improved quality of life. It is essential to advise patients to avoid strenuous activities for the initial two days after the injection, as with any invasive joint procedure. Some temporary injection-related side effects, such as mild to moderate pain at the injection site or swelling around the knee, may occur during the first week following the injection.
Research has indicated that viscosupplementation can delay the time to total knee joint replacement. Given the long-lasting and sustained effects of Arthrosamid, it is expected to offer similar advantages.
Although the precise mechanism of pain relief is still under investigation, Arthrosamid functions to cushion the joint. Clinical trials have demonstrated its ability to reduce pain, alleviate stiffness, and improve mobility, resulting in long-lasting relief and an overall improvement in quality of life. Arthrosamid has also been proven to be safe for use.
Prior to receiving an Arthrosamid injection, a local anaesthetic will be administered to numb the region surrounding the knee. During clinical trials, the most prevalent side effects were mild to moderate injection-related pain and/or mild swelling during the first few weeks to months following the injection.